All study participants must be registered into the mandatory POMALYST REMS program and be willing and able to comply with the requirements of the POMALYST REMS program
All study participants in the United States (US) must be consented to and registered into the mandatory revlimid (lenalidomide) REMS program and be willing and able to comply with the requirements of revlimid REMS
All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program
All study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS)(TM) program, and be willing and able to comply with the requirements of the POMALYST REMS(TM) program; for subjects enrolled outside of the United States, Pomalidomide counseling but be completed by a designated counselor
Willing to be registered into the mandatory REVLIMID REMS program, and willing and able to comply with the requirements of the REVLIMID REMS program
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory pomalidomide (POMALYST) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS program
All study participants must be registered into the mandatory Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered in the Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategy (RevREMS) program and be willing and able to comply with the requirements of REMS program
All study participants must be registered into the mandatory Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of REMS
All study participants must be registered into the mandatory Revlimid REMS program and be willing to comply with its requirements; per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS program
All subjects must agree to comply with and be enrolled in Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of Revlimid REMS; NOTE: females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMSTM program
Willing to follow the requirements of the Pomalyst REMS program
All study participants must be registered into the mandatory pomalidomide (POMALYST) Risk Evaluation and Mitigation Strategy (REMS) program and be willing and able to comply with the requirements of the POMALYST REMS program
Agree to be registered in and comply with all requirements of the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program (Cohorts B, C, E)
Agree to be registered in and comply with all requirements of the Pomalyst REMS program (Cohort F)
Willing to be registered into the mandatory REVLIMID REMS program, and willing and able to comply with the requirements of the REVLIMID REMS program
Willing to follow the requirements of the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
Registered into Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
All study participants must be registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants in the US must be consented to and registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program and be willing and able to comply with the requirements of Revlimid REMS
Willing to adhere to the guidelines of the Revlimid REMS (formerly known as RevAssist) program\r\n* NOTE: The counseling must be documented
All study participants must agree to be registered into the mandatory REVLIMID REMS program, and be willing and able to comply with the requirements of the REVLIMID REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must agree to be registered into the mandatory POMALYST Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
Willing and able to register into and comply with the mandatory requirements of Celgene’s REVLIMID REMS program
All study participants must be registered into the mandatory Revlimid REMS program and be willing to comply with its requirements; per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS), and be willing and able to comply with the requirements of the Revlimid REMS
All participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the Revlimid REMS
All study participants be willing and able to comply with the requirements of the Risk Evaluation and Mitigation Strategies (REMS) program
Patient enrolling to this study must agree to register to the mandatory REVLIMID Risk Evaluation and Mitigation Strategy (REMS [TM]) program, and be willing and able to comply with the requirements of (REVLIMID REMS [TM])
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMS program
All study participants must be willing to be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program after completion of induction chemoimmunotherapy and prior to maintenance therapy, and be willing and able to comply with the requirements of the Revlimid REMS program
All study participants must be registered into the mandatory POMALYST REMS™ program, and be willing and able to comply with the requirements of the POMALYST REMS™ program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the Revlimid REMS program
All study participants must agree to be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of Revlimid REMS
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the Revlimid REMS program
Registered into mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program
All patients must be registered in and must comply with all requirements of the Revlimid Rems program.
All study participants must be registered into the mandatory pomalidomide (POMALYST) REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program
All study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS program
Willing and able to comply with the requirements of the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
Willing to be registered into the mandatory POMALYST REMS (TM) program, and willing and able to comply with the requirements of the POMALYST REMS (TM) program
If assigned to receive lenalidomide, patient must be registered into the mandatory Revlimid REMS program and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMS
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program and be willing to comply with its requirements; per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS program
Patients must be registered to the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)™ program and must be willing and able to comply with the requirements of the Revlimid REMS™ program
All study participants must be registered into the mandatory Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMS
All study participants must be registered into the mandatory Revlimid REMS ™ Revlimid REMS™ program, and be willing and able to comply with the requirements of Revlimid REMS™
All study participants must be registered into the mandatory Revlimid REMS program, and be\r\nwilling and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)TM program, and be willing and able to comply with the requirements of the Revlimid REMSTM program; females of childbearing potential must adhere to the scheduled pregnancy testing and contraception as required in the Revlimid REMSTM program; a female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patient agrees that if randomized to Arms C or D, and proceeding onto Arms G or H, they must register into the mandatory Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of Rems
All study participants must be registered into the mandatory Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of REMS
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program
All study participants who will receive lenalidomide must be registered into the mandatory Revlimid REMS(TM) program, and be willing and able to comply with the requirements of the REMS(TM) program
All study participants enrolled in the lenalidomide containing cohort (cohort 2) must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program
All patients enrolled into this trial, must be registered in and must comply with all requirements of the POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS) program
All study participants must be registered into the mandatory Revlimid REMS program and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory electronic Risk Evaluation and Mitigation Strategies (eREMS) program, and be willing and able to comply with the requirements of REMS
All study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS program
All study participants enrolled in the United States must be registered into the mandatory REVLIMID Rems program and be willing and able to comply with the requirements of REVLIMID Rems
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory POMALYST Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS program
All study participants must be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program
Subjects must agree to follow all Guidelines from REVLIMID REMS Program or POMALYST REMS
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of Revlimid REMS program
All study participants must be registered into the mandatory Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of REMS
Patient must be registered into the mandatory Revlimid REMS program and be willing and able to comply with the requirements of Revlimid REMS
All study participants must be registered into the mandatory electronic Risk Evaluation and Mitigation Strategies (eREMS) program, and be willing and able to comply with the requirements of REMS
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMS program
All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the Revlimid REMS program
All study participants must be registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMS
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be willing to be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)® program, and be willing and able to comply with the requirements of the REMS® program; NOTE: Actual registration in the Revlimid REMS® program may occur after the patient is randomized since this requirement only applies to patients randomized to Arm A
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)® program, and be willing and able to comply with the requirements of Revlimid REMS®
All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of Revlimid REMS®; drug dispensing must come from the Celgene approved pharmacy, Biologics (Clinical Trials Services)
All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of Revlimid REMS®
All study participants must be registered into the mandatory lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS®) program, and be willing and able to comply with the requirements of the REMS® program
Willing to be registered into the mandatory Revlimid REMS® program, and willing and able to comply with the requirements of the REMS® program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMs program; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program
STEP I: Patient enrolling to this study must agree to register to the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
STEP II: Patient enrolling to this study must agree to register to the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist
All study participants must be willing to register with the mandatory RevAssist program and be willing to comply with its requirements
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
Subject is registered into the mandatory RevAssist® program, and is willing and able to comply with the requirements of RevAssist® program.
Patient agrees that if randomized to Arms C or D, and proceeding onto Arms G or H, they must register into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
Must be registered into the mandatory RevAssist® program and be willing and able to comply with the requirement of RevAssist®
Willingness to participate in the RevAssist program
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
Agreement to participate in RevAssist® Program
All subjects must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®. All counseling will be done through RevAssist®.
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
All study participants must be registered into the mandatory Revlimid assistance (RevAssist) program, and be willing and able to comply with the requirements of RevAssist
All study participants must be registered into the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Negative urine or serum pregnancy test for women of childbearing potential\r\n* NOTE: females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must agree to adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Persons able to become pregnant must be willing to adhere to the scheduled pregnancy testing as required in the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only \r\n* NOTE: Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential are willing and able to adhere to the scheduled pregnancy testing as required by Celgene’s REVLIMID REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Women of childbearing potential: adhere to scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program
Lactating or pregnant patients or patients of reproductive potential not willing to use effective methods of contraception and adhere to the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program
Females of childbearing potential must be willing to adhere to the scheduled pregnancy testing as required by the Revlimid REMS program
Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS (TM) program
If assigned to receive lenalidomide and a female of reproductive potential, must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Women must not be pregnant or breast-feeding\r\n* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program\r\n* All females of childbearing potential must have a blood test within 2 weeks prior to registration to rule out pregnancy \r\n* Pregnancy testing is not required for post-menopausal or surgically sterilized women
Females of reproductive potential who will receive lenalidomide must adhere to the scheduled pregnancy testing as required in the Revlimid REMS(TM) program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Female subject of childbearing potential must have a negative serum pregnancy 10-14 days prior to registration, and again within 24 hours prior to the first dose of lenalidomide; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of childbearing potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program; NOTE: This requirement only applies to patients randomized to Arm A
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the lenalidomide REMS program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS)® program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program